Clyde Biosciences is the leading cardiac cell analysis solution provider, used by the biopharma industry to help bring better, safer drugs to market. Our services are conducted on the CellOPTIQ® platform, a unique technology designed to eliminate the risk of false positive or false negative results. CellOPTIQ® provides clients with unparalleled data at a time when the industry needs it most, offering greater data resolution than any other assay, doing so in one experiment. With over 100 years of combined electrophysiology and computational experience Clyde Biosciences’ scientists work with pharmaceutical companies to design testing, data interpretation, and reporting packages that suit the efficacy and safety assessment objectives. HOW WE WORK… ◾Once our client’s objectives are clear, we produce a detailed proposal for work to be conducted, including timing and price. ◾We allocate a scientific lead and start to schedule laboratory time for the project. ◾Upon completion of the laboratory work, a report will be produced commensurate with your objectives. Our data is used across discovery from lead optimisation through to confirmatory safety studies. WHAT WE DO… ◾CiPA Assay (we are the only optical platform used in the major international CiPA Initiative) ◾Mechanistic CV Toxicity Assay ◾hiPSC Cardiomyocyte Characterisation & Validation Assay ◾Voltage Assay ◾Calcium Assay ◾Contractility Assay ◾In Silico Modelling ◾Custom R&D WE AIM TO MAKE WORKING WITH CLYDEBIO AS SIMPLE AS POSSIBLE offering: Efficient turnaround (most standard projects are completed within 2-4 weeks) Compound collection (we can collect compounds from you, so you don’t have to worry about shipping) Cell delivery (We can have cells delivered directly to our labs, saving you the hassle of ordering and shipping) To enquire about how we can help with your project, phone us on +44 (0) 1698 539 920, email us at info@clydebio.com or visit our website at https://www.clydebio.com/
